Safety of Infusing Rituximab at a More Rapid Rate in Patients with Rheumatoid Arthritis: Results from the RATE-RA Study

Authors

Charles H. Pritchard, Rheumatology Specialty Center
Maria W. Greenwald, Desert Medical Advances
Joel M. Kremer, Albany Medical College
Norman B. Gaylis, Arthritis & Rheumatic Disease Specialties
William Rigby, Dartmouth College

Document Type

Article

Publication Date

5-24-2014

Publication Title

BioMed Central Musculoskeletal Disorders

Department

Geisel School of Medicine

Abstract

As recommended in the current prescribing information, rituximab infusions in patients with rheumatoid arthritis (RA) take 4.25hours for the first infusion and 3.25hours for subsequent infusions, which is a burden on patients and the health care system. We therefore evaluated the safety of infusing rituximab at a faster rate for an infusion period of 2hours in patients with RA.

DOI

10.1186/1471-2474-15-177

Dartmouth Digital Commons Citation

Pritchard, Charles H.; Greenwald, Maria W.; Kremer, Joel M.; Gaylis, Norman B.; and Rigby, William, "Safety of Infusing Rituximab at a More Rapid Rate in Patients with Rheumatoid Arthritis: Results from the RATE-RA Study" (2014). Dartmouth Scholarship. 654.
https://digitalcommons.dartmouth.edu/facoa/654